TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04350970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal therapy
Description: All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The high flow nasal therapy was used during all exercise test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The NIV was used during all exercise test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The control test was performed with no additional therapy.
Study: NCT01544361

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7814, 1 MG/KG
Description: A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7814, 3 MG/KG
Description: A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7814, 10 MG/KG
Description: A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
Study: NCT00706030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study: NCT00433407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study: NCT03851783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solar-powered oxygen
Description: Constant and reliable administration of oxygen, using solar panels to power an oxygen concentrator and deliver medical grade oxygen at 1-5L/min.
Study: NCT02219139

Intervention type: DEVICE
Group type: OTHER
Intervention: ESTA abutment Roxolid
Description: Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
Study: NCT00865215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride Extended Release Capsules 160 mg
Description: A: Experimental Subjects received Actavis formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INDERAL® LA 160 mg Capsules, single dose
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
Study: NCT05103865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment
Study: NCT04315896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: hydroxychloroquine 400mg day for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study: NCT01544361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7814, 20 MG/KG
Description: A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
Study: NCT02934347

Intervention type: PROCEDURE
Intervention: 25 degree back-up position
Description: To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
Study: NCT02208492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carabamazepine
Description: Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
Study: NCT02404194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training
Description: Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer Games
Description: The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
Study: NCT03548389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin contact
Description: By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
Study: NCT01308866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share decision tool
Study: NCT03460431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser 10,600nm
Description: fractional CO2 laser 10,600nm session, every month for 4 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser 10,600nm
Description: fractional CO2 laser 10,600nm session, every month for 4 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd YAG laser1064 nm
Description: Nd YAG laser1064 nm laser session, every month for 4 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd YAG laser1064 nm
Description: Nd YAG laser1064 nm laser session, every month for 4 months
Study: NCT00783484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc +PF-03716539
Description: Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
Study: NCT02801266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence informed birth control counseling
Description: Counselors underwent training on the use of 10 best practices for contraceptive counseling.
Study: NCT01710137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02668367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTA-C585 oral capsules
Description: BTA-C585; Multiple ascending doses from 100 mg to 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BTA-C585 matching placebo
Description: Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
Study: NCT04121676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2373
Description: An Anti-CD137 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2373
Description: An Anti-CD137 Monoclonal Antibody
Study: NCT02715687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Will receive 30 days treatment with oral amniodarone of 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive 30 days treatment with oral placebo of 200mg
Study: NCT01934569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771
Description: PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
Study: NCT04121676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2373
Description: An Anti-CD137 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Anti-CTLA-4 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Anti-CTLA-4 Monoclonal Antibody
Study: NCT04586985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-6058/placebo oral capsule(s)
Description: Subjects will receive FTX-6058 or matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-6058/placebo oral capsule(s)
Description: Subjects will receive FTX-6058 or matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-6058 - Two Dosing Periods
Description: Subjects will receive FTX-6058
Study: NCT06773702

Intervention type: OTHER
Intervention: gastroenterology and otolaryngological evaluation
Description: * Gastroenterology evaluation: presence and intensity of esophageal symptoms of gastro esophageal reflux disease, high-resolution esophageal manometry, and 24-hour pH-impedancometry in the absence of PPI therapy.~* otolaryngological evaluation: presence and intensity of laryngopharyngeal reflux symptoms, laryngoscopy.
Study: NCT04586985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-6058 / Midazolam Syrup
Description: Subjects will receive FTX-6058 and midazolam syrup
Study: NCT01710137

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Study: NCT00689117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT Gel
Description: Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Gel (clindamycin )
Description: Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
Study: NCT04586985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTX-6058/placebo oral capsule(s)
Description: Subjects will receive FTX-6058 or matching placebo.
Study: NCT03867045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usability of an electronic symptom management application
Description: Usability of an electronic symptom management application in a pilot group of patients receiving cabozantinib for mRCC through data analytics and feedback from users
Study: NCT03274921

Intervention type: DIAGNOSTIC_TEST
Intervention: Biological determination
Description: Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Biological determination
Description: Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients
Study: NCT05008094

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole-exome sequencing
Description: Whole-exome sequencing with the focus on Parkinson's disease loci.

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole-exome sequencing
Description: Whole-exome sequencing with the focus on Parkinson's disease loci.

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole-exome sequencing
Description: Whole-exome sequencing with the focus on Parkinson's disease loci.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota sequencing
Description: Next generation sequencing of microbiota from stool and saliva samples.
Study: NCT00689117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin Gel (tretinoin)
Description: Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
Study: NCT02204124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thunderbeat
Description: Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care scissors, ligatures, clips, and sutures
Study: NCT00970385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP21
Description: CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5.
Study: NCT05008094

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiota sequencing
Description: Next generation sequencing of microbiota from stool and saliva samples.
Study: NCT00970385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP/ABVD
Description: VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy consolidation
Description: The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy consolidation
Description: The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
Study: NCT03129399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope
Description: nasal intubation using King Vision video laryngoscope Device after general anesthesia induction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC video laryngoscope
Description: nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
Study: NCT00081094

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 18F-Fluorodeoxyglucose-PET (FDG-PET)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 11Carbon-Acetate-PET
Study: NCT01697410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
Study: NCT02058524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Study: NCT00988650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isocaloric diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: free living conditions
Study: NCT04176653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Description: IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
Study: NCT05008094

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging of the brain focused on detection of free water in Substantia Nigra using a novel protocol.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging of the brain focused on detection of free water in Substantia Nigra using a novel protocol.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial ultrasound and Electroencephalography
Description: Transcranial ultrasound of Substantia Nigra, as well as high resolution EEG.
Study: NCT04176653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Description: IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Description: IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Description: IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Description: IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
Study: NCT02706990

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica KR
Description: Kinematic retaining total knee implant

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica PS
Description: Posterior stabilized total knee implant
Study: NCT03923244

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OSDI survey
Description: Normal patient consultation schedule for cataract surgery with:~* Preoperative appointment scheduled for the patient~* Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~* Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~* An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~* Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
Study: NCT00504946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone, lactose
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose
Study: NCT05008094

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial ultrasound and Electroencephalography
Description: Transcranial ultrasound of Substantia Nigra, as well as high resolution EEG.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA (Enzyme-Linked Immunosorbent Assay)
Description: ELISA (Enzyme-Linked Immunosorbent Assay) will be used to assess the inflammatory state, glial functions, and disease progression will also be determined through specific markers in the participant's serum and plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA (Enzyme-Linked Immunosorbent Assay)
Description: ELISA (Enzyme-Linked Immunosorbent Assay) will be used to assess the inflammatory state, glial functions, and disease progression will also be determined through specific markers in the participant's serum and plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescent correlation spectroscopy (FCS)
Description: Fluorescent correlation spectroscopy (FCS), more specifically, ThT fluctuating intensity fluorescent analysis (FIFA) will be used to determine the existence of pathological conformation protein forms and their relation to the disease's grade and therapy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescent correlation spectroscopy (FCS)
Description: Fluorescent correlation spectroscopy (FCS), more specifically, ThT fluctuating intensity fluorescent analysis (FIFA) will be used to determine the existence of pathological conformation protein forms and their relation to the disease's grade and therapy.
Study: NCT00428675

Intervention type: OTHER
Intervention: ACI instrument
Description: Following ethics approval, 17 experts in symptom management assisted with content validation during the pilot phase. In the main study, participants complete the FACT-F, the POMS-Vsf, and the ACI Instrument. A research assistant collected demographic information and assigned an ECOG score.
Study: NCT02063035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single topical application of matching placebo, which is 100 mL of normal saline.
Study: NCT03315351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.~The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-scan
Description: The patient will undergo 2 PET-scan during the clinical trial:~* the first one is additional to the brachytherapy~* the second one is realized 4 months after the brachytherapy